[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60230160D1 - 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen - Google Patents

2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen

Info

Publication number
DE60230160D1
DE60230160D1 DE60230160T DE60230160T DE60230160D1 DE 60230160 D1 DE60230160 D1 DE 60230160D1 DE 60230160 T DE60230160 T DE 60230160T DE 60230160 T DE60230160 T DE 60230160T DE 60230160 D1 DE60230160 D1 DE 60230160D1
Authority
DE
Germany
Prior art keywords
treatment
arylaminopyrimidine
gsk3
related diseases
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230160T
Other languages
English (en)
Inventor
Stefan Berg
Ratan Bhat
Sven Hellberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60230160D1 publication Critical patent/DE60230160D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DE60230160T 2001-02-20 2002-02-18 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen Expired - Lifetime DE60230160D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26990301P 2001-02-20 2001-02-20
PCT/SE2002/000270 WO2002066480A2 (en) 2001-02-20 2002-02-18 2-arylamino-pyrimidines for the treatment of gsk3-related disorders

Publications (1)

Publication Number Publication Date
DE60230160D1 true DE60230160D1 (de) 2009-01-15

Family

ID=23029104

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230160T Expired - Lifetime DE60230160D1 (de) 2001-02-20 2002-02-18 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen

Country Status (17)

Country Link
US (1) US7078410B2 (de)
EP (1) EP1423388B1 (de)
JP (1) JP4309657B2 (de)
KR (1) KR20030076688A (de)
CN (1) CN100415744C (de)
AT (1) ATE416175T1 (de)
BR (1) BR0207096A (de)
CA (1) CA2435177A1 (de)
DE (1) DE60230160D1 (de)
ES (1) ES2316546T3 (de)
HK (1) HK1094697A1 (de)
IL (1) IL156784A0 (de)
MX (1) MXPA03007266A (de)
NO (1) NO20033677L (de)
NZ (1) NZ527009A (de)
WO (1) WO2002066480A2 (de)
ZA (1) ZA200306175B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003265336B8 (en) 2002-07-29 2009-04-23 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2508194C (en) * 2002-12-03 2011-05-24 Kyorin Pharmaceutical Co., Ltd. Use of ibudilast as a phosphodiesterase 10a inhibitor
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
EP1670460B1 (de) 2003-10-10 2014-11-26 Bristol-Myers Squibb Company Pyrazol-derivate als cannabinoid-rezeptor-modulatoren
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
JP2008515986A (ja) * 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
MX2007007272A (es) * 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
US20060204980A1 (en) * 2004-12-28 2006-09-14 Altieri Dario C Colorectal cancer therapies
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
EP1910367A2 (de) * 2005-05-20 2008-04-16 Alantos Pharmaceuticals, Inc. Pyrimidin- oder triazinkondensierte bicyclische metalloproteaseinhibitoren
EP1904457B1 (de) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur inhibierung des jak-pfades
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1942897A1 (de) * 2005-10-03 2008-07-16 AstraZeneca AB Verwendung von pyrimidin-derivaten bei der herstellung eines medikaments zur prävention und/oder behandlung von alzheimer-krankheit
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
CN101410397A (zh) * 2006-03-31 2009-04-15 诺瓦提斯公司 有机化合物
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
JP2009542604A (ja) * 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
WO2008068171A1 (en) * 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as jnk modulators
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
EP2114941B1 (de) 2006-12-22 2015-03-25 Astex Therapeutics Limited Bicyclische heterocyclische verbindungen als fgfr-inhibitoren
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
US8067409B2 (en) 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
PL2265607T3 (pl) 2008-02-15 2017-07-31 Rigel Pharmaceuticals, Inc. Związki pirymidyno-2-aminowe i ich zastosowanie jako inhibitory kinaz JAK
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8680113B2 (en) 2008-07-01 2014-03-25 Ptc Therapeutics, Inc. BMI-1 protein expression modulators
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
NZ590283A (en) 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
EP2326622A1 (de) 2008-07-28 2011-06-01 Gilead Sciences, Inc. Cycloalkyliden- und heterocycloalkyliden-histondeacetylasehemmerverbindungen
UY32203A (es) * 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia
CN101735211B (zh) * 2008-11-04 2012-11-14 复旦大学 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8178529B2 (en) 2009-04-15 2012-05-15 Astrazeneca Ab Imidazole substituted pyrimidines
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
US8258316B2 (en) 2009-06-08 2012-09-04 Gilead Sciences, Inc. Alkanoylamino benzamide aniline HDAC inhibitor compounds
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
EA020847B1 (ru) 2009-10-30 2015-02-27 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
CN102391264A (zh) * 2011-09-21 2012-03-28 河北九派制药有限公司 6-溴咪唑并[1,2-a]吡啶的制备方法
EP2671885A1 (de) 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-Oxadiazol- und Imidazo-Thiadiazolderivate
EP2863909B1 (de) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Kombinationen mit 4-methyl-[1,2,4]triazolo[4,3-a]chinoxalinverbindungen als pde-2-hemmern und pde-10-hemmern zur verwendung in der behandlung von neurologischen und stoffwechselerkrankungen
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
CA2886187C (en) * 2012-09-28 2020-04-14 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
PT2922828T (pt) 2012-11-21 2020-10-12 Ptc Therapeutics Inc 4,6-diamino-pirimidina derivados como inibidores de bmi-1 para tratamento do cancro
CN105683166B (zh) * 2013-08-30 2020-06-16 Ptc医疗公司 取代的嘧啶Bmi-1抑制剂
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN106362155A (zh) * 2016-10-08 2017-02-01 无锡汉强医药科技有限公司 Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用
JP2020502117A (ja) 2016-12-16 2020-01-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺生物剤化合物
US10745400B2 (en) 2018-03-14 2020-08-18 Vanderbuilt University Inhibition of BMP signaling, compounds, compositions and uses thereof
CN113164479A (zh) 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
KR102249521B1 (ko) 2018-11-14 2021-05-07 아이알링크 주식회사 스마트폰과 동기화되는 pc 인터페이스 장치 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47583A1 (en) * 1986-01-13 1998-04-17 American Cyanamid Co 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
EP1317433A2 (de) * 2000-09-06 2003-06-11 Chiron Corporation Inhibitoren von glycogen synthase kinase 3

Also Published As

Publication number Publication date
CN100415744C (zh) 2008-09-03
BR0207096A (pt) 2004-01-20
ES2316546T3 (es) 2009-04-16
JP2004522777A (ja) 2004-07-29
KR20030076688A (ko) 2003-09-26
NZ527009A (en) 2006-04-28
CA2435177A1 (en) 2002-08-29
CN1823064A (zh) 2006-08-23
WO2002066480A2 (en) 2002-08-29
EP1423388A2 (de) 2004-06-02
IL156784A0 (en) 2004-02-08
EP1423388B1 (de) 2008-12-03
NO20033677L (no) 2003-10-02
NO20033677D0 (no) 2003-08-19
US20040106574A1 (en) 2004-06-03
HK1094697A1 (en) 2007-04-04
JP4309657B2 (ja) 2009-08-05
US7078410B2 (en) 2006-07-18
ZA200306175B (en) 2005-01-26
WO2002066480A3 (en) 2004-04-01
MXPA03007266A (es) 2003-12-04
ATE416175T1 (de) 2008-12-15

Similar Documents

Publication Publication Date Title
DE60230160D1 (de) 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
ATE545660T1 (de) Verfahren zur herstellung von niedermolekularem kationischem polygalactomannan mit verringertem geruch
BR0210680A (pt) Processo para a hidrólise de proteìnas do leite
BR0108734A (pt) Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas
RU2006116252A (ru) Водные композиции, содержащие метронидазол
RO117145B1 (ro) Emulsie sau soluţie apoasă, mucoadezivă
DE602004024571D1 (de) Pharmazeutische formulierungen für die verzögerte freisetzung von ein oder mehr wirkstoffen und ihre therapeutische anwendungen
DE59607548D1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikrokapseln sowie nach diesem verfahren hergestellte mikrokapseln
DE60107252D1 (de) Antimikrobielle zusammensetzung zur behandlung von rindermastitis
CA2527120A1 (en) Stable aqueous solution of natamycin fungicide
DE69807818D1 (de) Mittel zum eintauchen von zitzen
RU95101376A (ru) Способ снижения содержания органического и неорганического галогена в водном растворе азотсодержащей смолы и применение водного раствора азотсодержащей смолы
DE60034601D1 (de) Verfahren zur herstellung von polyphenolischen adhäsionsproteinen
ATE445648T1 (de) Verfahren zur herstellung von chitosan
CA2015235A1 (en) Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent
TW200519080A (en) Agent containinf (2R)-2-propyloctanic acid as effective component
DE60220193D1 (de) Einwertiges salz verbessert die löslichkeit von milchproteinkonzentrat
WO2002067952A8 (en) Prophylactic teat treatment
DE69811758D1 (de) Verwendung von Hyaluronsäure zur Herstellung einer wässrigen Lösung verwendbar als intra-artikulare Reinigungslösung
ATE386734T1 (de) Verfahren zur herstellung von (4-hydroxy-6-oxo- tetrahydropyran-2-yl) acetonitril und dessen derivaten
KR960030812A (ko) 취반용 기능미의 제조방법
BRPI0416427A (pt) suspensão aquosa e método de preparação de suspensão aquosa
NO20033705L (no) Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr
JPS632911A (ja) 防カビ剤
SE0101307D0 (sv) An effervescent solid composition of matter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition